AI meets biology: How cellular intelligence is redefining stem cell therapy

Cellular Intelligence, a Boston-based biotech company co-founded by Israeli entrepreneur Dr. Micha Breakstone, is leveraging artificial intelligence to revolutionize stem cell therapy. The company combines computational modeling with regenerative medicine, aiming to address diseases like Parkinson’s, Type 1 diabetes, epilepsy, and macular degeneration. Its platform integrates high-throughput data and AI to improve the consistency and scalability of cell therapies, a major challenge in the field. Breakstone, previously the co-founder of Israeli tech company Chorus.ai, has positioned Cellular Intelligence at the intersection of AI and biology. The company’s scientific foundation includes collaborations with Harvard Medical School’s Prof. Allon Klein, developmental biologist Prof. Olivier Pourquie, and Dr. Nuno Mendonca, who leads the Parkinson’s program. Cellular Intelligence’s AI-driven approach decodes cell signaling rules, transforming biology from observation to predictive engineering. The platform uses large-scale cellular data and clinical feedback loops to refine therapies, ensuring they can be produced reliably at scale. The company recently acquired Novo Nordisk’s clinical-stage Parkinson’s cell therapy program, STEM-PD, which aims to replace lost dopamine-producing neurons. In mid-May, Cellular Intelligence hosted a symposium in Copenhagen, bringing together 28 experts in AI, biology, and regenerative medicine. Breakstone compared the potential of AI in cell fate engineering to the impact of AlphaFold in biology, emphasizing its transformative potential. The event highlighted the urgency of integrating AI into biological research to accelerate therapeutic breakthroughs for devastating diseases.